ORIGINAL RESEARCH

Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy

Marinos Tsiatas1* | Konstantine T. Kalogeras2,3* | Kyriaki Manousou4 | Ralph M. Wirtz5 | Helen Gogas6 | Elke Veltrup5 | Flora Zagouri7 | Georgios Lazaridis8 | Angelos Koutras9 | Christos Christodoulou10 | George Panteroudakis11 | Constantina Petaki12 | Dimitrios Bafaloukos13 | Dimitrios Pectasides14 | Paris Kosmidis15 | Epaminontas Samantas16 | Charisios Karanikiotis17 | Pavlos Papakostas18 | Meletios-Athanassios Dimopoulos7 | George Fountzilas2,19

1Department of Oncology, Athens Medical Center, Marousi, Greece
2Laboratory of Molecular Oncology, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki, Greece
3Translational Research Section, Hellenic Cooperative Oncology Group, Athens, Greece
4Section of Biostatistics, Hellenic Cooperative Oncology Group, Data Office, Athens, Greece
5STRATIFYER Molecular Pathology GmbH, Cologne, Germany
6First Department of Medicine, Laiko General Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
7Department of Clinical Therapeutics, Alexandria Hospital, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
8Department of Medical Oncology, Faculty of Medicine, School of Health Sciences, Papageorgiou Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
9Division of Oncology, Department of Medicine, University Hospital, University of Patras Medical School, Patras, Greece
10Second Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece
11Department of Medical Oncology, Ioannina University Hospital, Ioannina, Greece
12Department of Pathology, Metropolitan Hospital, Piraeus, Greece
13First Department of Medical Oncology, Metropolitan Hospital, Piraeus, Greece
14Oncology Section, Second Department of Internal Medicine, Hippokration Hospital, Athens, Greece
15Second Department of Medical Oncology, Hygeia Hospital, Athens, Greece
16Third Department of Medical Oncology, Agii Anargiri Cancer Hospital, Athens, Greece
17Department of Medical Oncology, 424 Army General Hospital, Thessaloniki, Greece
18Oncology Unit, Hippokration Hospital, Athens, Greece
19Aristotle University of Thessaloniki, Thessaloniki, Greece

Correspondence: Marinos Tsiatas, Department of Oncology, Athens Medical Center, Dostomou 5-7, Maroussi, 151 21

Abstract

Background: Tumor-infiltrating lymphocytes (TILs) have been shown to be of prognostic value in several cancer types. In early breast cancer, TILs have a...

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
1 | INTRODUCTION

It has been well established that cancer evolution largely depends on the evasion of the immune system by the tumor cells. In this dynamic process, the immune system plays a dual role and may eliminate tumor cells, thus suppressing tumor progression, but on the other hand, it can promote their survival, facilitating tumor growth by specifically modifying the tumor microenvironment. Tumor-infiltrating lymphocytes (TILs) have been extensively studied over the last two decades, and a growing body of evidence has provided insight on tumor immunogenicity.\(^1\,^3\) Initially, TILs were thought to be activated against tumor antigens and to be able to recognize and destroy cancer cells. Nevertheless, TILs are usually in an anergic state due to the ability of tumor cells to suppress antitumor immune activity, thus evading immunogenic death. This procedure, known as “immunoediting,” consists of three phases: the “elimination” phase, where immune effector cells recognize and eliminate cancer cells with great efficacy; the “equilibrium” phase, where tumor cells, following a selection procedure, gain a survival advantage and manage to evade recognition and elimination by the immune cells; and the late “escape” phase, where tumor is mainly characterized by an immunosuppressive environment, with the contribution of immune suppressor cells, leading to uncontrolled tumor growth.\(^4\)

Breast cancer, unlike other tumor types, such as melanoma, was historically considered as nonimmunogenic. However, recent studies have demonstrated that breast tumors are infiltrated by lymphocytes, with high numbers of TILs...
being present in more aggressive subtypes, such as HER2-positive and triple-negative (TN). Overall, breast cancer patients with more than 50% or 60% lymphocyte infiltration of their tumor bed or stroma (lymphocyte predominant breast cancer, LPBC type) have improved clinical outcomes.\(^5,6\)

More specifically, in HER2-positive and TN breast cancers, where the LPBC subtype is more common (approximately 20% of such tumors), even incremental increases in stromal or intratumoral TILs predict for better response to chemotherapy and survival.\(^5,8\) TILs in these subtypes are predominantly T cells and CD8\(^+\) T cells represent the subpopulation that is closely associated with favorable outcomes in terms of survival, especially in TN breast cancer patients.\(^9\) In HER2-positive breast cancers, the association of CD3\(^+\) and CD8\(^+\) T cells with improved survival is stronger in the hormone receptor-negative than in the hormone receptor-positive subtype, showing in part that hormone receptor positivity or negativity is a stronger factor than HER2 status in affecting T-cell infiltration in breast cancer.\(^10,11\)

Indeed, a recent systematic review has shown that hormone receptor-positive HER2-negative breast cancers demonstrate the lowest percentage of T-cell infiltration and the lowest incidence of LPBC (6% vs 20% in the TN subtype).\(^12\) This might be explained by the fact that luminal tumors have low expression of major histocompatibility complex molecules and, on the other hand, estrogen receptors are promoting a TH2 immune reaction, thus rendering these tumors less immunogenic, leading to decreased T-cell infiltration.\(^13,14\)

Among TILs, there are subtypes that inhibit T-cell activation, with FOXP3\(^+\) T-regulatory (Treg) cells representing the major component of this inhibition. Tregs affect CD8\(^+\) function and inhibit dendritic cell-mediated antigen presentation, as well as natural killer (NK) cell activation. However, the prognostic value of Tregs in breast cancer is controversial, as different studies have shown that Tregs are positively associated with poor survival,\(^15\) whereas other studies have demonstrated that high infiltration of Tregs is associated with better outcomes.\(^16,17\)

Moreover, the majority of breast cancer patients develop bone metastases, with the microenvironment of the host and its interactions with tumor cells playing a pivotal role in their progression.\(^18\) Receptor activator of nuclear factor-kB (RANK) with its ligand (RANKL) and the RANKL decoy receptor osteoprotegerin (OPG) is highly involved in many cell functions associated with formation and progression of bone metastases; we have recently demonstrated that low RANKL mRNA expression in tumor tissue of early breast cancer patients is of prognostic significance for increased risk of relapse and bone metastases.\(^19\) RANK and RANKL are expressed not only in tumor tissue but also in immune cells. For example, RANK is expressed in tumor-associated macrophages (TAMs) and NK cells, while RANKL has been reported to be expressed in activated T cells.\(^20\) Such expression may also play a role in the formation and progression of bone metastases, but this has yet to be elucidated.

In this study, we sought to investigate the prognostic value of T-cell marker mRNA expression (CD3, CD8, and FOXP3), as well as their association with TILs and RANK, RANKL, and OPG mRNA expression, in a large cohort of early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy in the context of two prospective phase III randomized trials.

## 2 | PATIENTS AND METHODS

### 2.1 | Patient population

This was a retrospective translational research study among 1681 patients with early breast cancer, enrolled in two prospective phase III adjuvant trials. The HE10/97 trial\(^21\) was a randomized phase III trial (ACTRN12611000506998) in patients with intermediate/high-risk operable breast cancer, comparing four cycles of epirubicin (E) followed by four cycles of intensified CMF (E-CMF) with three cycles of E, followed by three cycles of paclitaxel (T, Taxol\(^\text{®}\), Bristol Myers-Squibb, Princeton, NJ) followed by three cycles of intensified CMF (E-T-CMF). The current definition of high-risk breast cancer is based on the “International expert consensus on the primary therapy of early breast cancer 2007”.\(^22\) Specifically, high-risk patients were node-positive patients with 1-3 involved lymph nodes and ER and PgR absent, or HER2/neu gene overexpressed or amplified; or node-positive patients with four or more involved lymph nodes. The cycles were given every 2 weeks with G-CSF support. Dose intensity of all drugs in both treatment arms was identical, but cumulative doses and duration of chemotheraphy period differed. In total, 595 eligible patients entered the study in a period of 3.5 years (1997-2000).

The HE10/00 trial\(^23,24\) was a randomized phase III trial (ACTRN12609001036202), in which patients were treated with E-T-CMF (exactly as in the HE10/97 trial) or with four cycles of epirubicin/paclitaxel (ET) combination (given on the same day) every 3 weeks followed by three cycles of intensified CMF (E-CMF) with three cycles of E, followed by three cycles of paclitaxel (T, Taxol\(^\text{®}\), Bristol Myers-Squibb, Princeton, NJ) followed by three cycles of intensified CMF (E-T-CMF). The current definition of high-risk breast cancer is based on the “International expert consensus on the primary therapy of early breast cancer 2007”.\(^22\) Specifically, high-risk patients were node-positive patients with 1-3 involved lymph nodes and ER and PgR absent, or HER2/neu gene overexpressed or amplified; or node-positive patients with four or more involved lymph nodes. The cycles were given every 2 weeks with G-CSF support. Dose intensity of all drugs in both treatment arms was identical, but cumulative doses and duration of chemotherapy period differed. In total, 1086 eligible patients entered the study in a period of 5 years (2000-2005).

HER2-positive patients received trastuzumab upon relapse, as previously described\(^25\); no anti-HER2 treatment was given in the adjuvant setting. Treatment schedules for the two studies are shown in Table S1. Baseline characteristics and clinical outcomes of both trials have already been described.\(^21,23,24,26\) Primary tumor diameter, axillary nodal
status, and tumor grade were obtained from the pathology report. Clinical protocols were approved by local regulatory authorities, while the present translational research study was approved by the “Papageorgiou” Hospital Institutional Review Board (July 15, 2013) and the Bioethics Committee of the Aristotle University of Thessaloniki School of Medicine (December 18, 2013). All patients signed a study-specific written informed consent before randomization, which in addition to giving consent for the trial allowed the use of biological material for future research purposes. All clinical investigations related to this study have been conducted according to the principles expressed in the Declaration of Helsinki.

2.2 | Tissue microarray (TMA) construction

Formalin-fixed paraffin-embedded (FFPE) tumor tissue samples from 975 patients (58.0% of 1681 randomized patients) were obtained during the initial breast surgery, before the initiation of adjuvant chemotherapy, and were collected retrospectively in the first trial (HE10/97) and prospectively in the second (HE10/00). The REMARK diagram for the study is shown in Figure 1. Hematoxylin-eosin stained sections from the tissue blocks were reviewed by two experienced breast cancer pathologists, and the most representative tumor areas were marked for the construction of the TMA blocks with the use of a manual arrayer (Model I, Beecher Instruments, San Prairie, WI), as previously described. Each case was represented by two tissue cores, 1.5 mm in diameter, obtained from the most representative areas of primary invasive tumors or in some cases (9.6%) from synchronous axillary lymph node metastases, and re-embedded in 51 microarray blocks. Each TMA block contained 38 to 66 tissue cores from the original tumor tissue blocks, while cores from various neoplastic, non-neoplastic, and reactive tissues were also included, serving as orientation controls for slide-based assays. Cases not represented, damaged, or inadequate on the TMA sections were recut from the original blocks, when material was available, and these sections were used for protein expression analysis. Stromal TILs density, that is, intratumoral stromal area occupied by mononuclear inflammatory cells over total intratumoral stromal area, was previously evaluated in whole H&E sections for the present cohort; this variable was here assessed as continuous for associations and in 10% increments for outcome analyses.

2.3 | Immunohistochemistry (IHC)

Immunohistochemical labeling was performed according to standard protocols on serial 2.5 μm thick sections from the original blocks or the TMA blocks. To assure optimal reactivity, immunostaining was applied 7 to 10 days after sectioning at the Laboratory of Molecular Oncology of the Hellenic Foundation for Cancer Research, Aristotle University of Thessaloniki School of Medicine. The staining procedures for HER2 (A0485 polyclonal antibody, dilution 1:200, Dako, Glostrup, Denmark), estrogen receptor (ER, clone 6F11, dilution 1:70, NovocastraTM, Leica Biosystems, Newcastle, UK), progesterone receptor (PgR, clone 1A6, dilution 1:70, NovocastraTM, Leica Biosystems), and Ki67 (clone MIB-1, dilution 1:70, Dako) were performed using a Bond MaxTM autostainer (Leica Microsystems, Wetzlar, Germany), as previously described in detail.

2.4 | Interpretation of the IHC results

The evaluation of all IHC sections was made by two experienced breast cancer pathologists, blinded as to the patients’ clinical characteristics and survival data, according to existing established criteria, as previously described. Briefly, HER2 protein expression was scored in a scale from 0 to 3+, the latter corresponding to uniform, intense membrane staining in >30% invasive tumor cells; ER and PgR were considered positive if staining was present in ≥1% of tumor cell nuclei; and, for Ki67, the expression was defined as low (<20%) or high (≥20%) based on the percentage of stained/unstained nuclei from the tumor areas. If one of the tissue cores was lost or damaged, the overall score was determined from the remaining one. When whole tissue sections were used, the entire tumor area was evaluated.

2.5 | Fluorescence in situ hybridization (FISH)

TMA sections or whole tissue sections (5 μm thick) were used for FISH analysis, using the ZytoLight® SPEC HER2/
TOP2A/CEP17 triple color probe (Z-2073, ZytoVision, Bremerhaven, Germany), as previously described.\textsuperscript{39} FISH was performed according to the manufacturer’s protocol with minor modifications in all cases, not only the HER2 IHC 2+ cases.

Digital images were constructed using specifically developed software for cytogenetics (XCyto-Gen, ALPHELYS, Plaisir, France). Processed sections were considered eligible for FISH evaluation according to the ASCO/CAP criteria.\textsuperscript{36} For the evaluation of the HER2 gene status, nonoverlapping nuclei from the invasive part of the tumor were randomly selected, according to morphological criteria using DAPI staining, and scored. Twenty tumor nuclei were counted according to Press et al.\textsuperscript{40} The HER2 gene was considered to be amplified when the HER2/CEP17 ratio was $>2.2$,\textsuperscript{36} or the mean HER2 copy number was $>6$.\textsuperscript{41} In cases with values at or near the cutoff (1.8-2.2), 20-40 additional nuclei were counted and the ratio was recalculated. In cases with a borderline ratio, additional FISH assays were performed in whole sections.\textsuperscript{42} The data from the evaluation of TOP2A gene status were neither analyzed nor presented in the present manuscript.

### 2.6 RNA isolation and quantitative reverse transcription-polymerase chain reaction (qRT-PCR) assessment

Prior to RNA isolation, macrodissection of tumor areas was performed in most (69%) of the FFPE sections (all sections with <50% tumor cell content). More than one FFPE section (2-8 sections, 10 μm thick) was used for RNA extraction when the tumor surface of a given sample was less than 0.25 cm$^2$. From each FFPE section or macrodissected tissue fragments, RNA was extracted using a standardized fully automated isolation method for total RNA from FFPE tissue, based on germanium-coated magnetic beads (XTRAKT kit, STRATIFYER Molecular Pathology GmbH, Cologne, Germany) in combination with a liquid handling robot (XTRAKT XL, STRATIFYER Molecular Pathology GmbH), as previously described in detail.\textsuperscript{19,32,34,35,43,44} The method involves extraction-integrated deparaffinization and DNase I digestion steps. The quality and quantity of RNA were checked by measuring CALM2 expression as a surrogate for amplifiable mRNA by qRT-PCR. CALM2 was used as endogenous reference, as it had previously been identified as being highly and stably expressed among breast cancer tissue samples.\textsuperscript{45} Of the 975 FFPE tumor tissue samples collected, 857 (87.9%) had enough material left for RNA isolation needed for this study.

qRT-PCR primers and labeled hydrolysis probes were selected using Primer Express$^\text{®}$ Software, versions 2.2 and 3 (Applied Biosystems/Life Technologies, Karlsruhe, Germany), according to the manufacturer’s instructions, and were controlled for single nucleotide polymorphisms. All primers, probes, and amplicons were checked for their specificity against nucleotide databases at NCBI using Basic Local Alignment Search Tool (BLAST). Primers and probes were purchased from Eurogentec S.A. (Seraing, Belgium). For qRT-PCR, the amplification efficiency was tested, aiming to reach comparable efficiency of >90% (efficiency range from 91% to 108%). Primers and hydrolysis probes were diluted to 100 μmol/L, using a stock solution with nuclease-free water (Life Technologies GmbH, Darmstadt, Germany).\textsuperscript{19,34,35,44} qRT-PCR was applied for the relative quantification (RQ) of RANK, OPG, and RANKL. The Primer/Probe (YakimaYellow/FAM-labeled) sets used for amplification of the target and reference genes are shown in Table 1.

For qRT-PCR, 0.5 μmol/L of each primer and 0.25 μmol/L of each probe were used. All quantitative reverse transcription PCRs were performed in duplicates using the SuperScript$^\text{®}$ III Platinum$^\text{®}$ One-Step qRT-PCR kit (Invitrogen/Life Technologies, Darmstadt, Germany) according to the manufacturer’s instructions. Experiments were performed on a Stratagene Mx3005p (Agilent Technologies, Waldbronn, Germany) with 30 minutes at 50°C and 2 minute at 95°C followed by 40 cycles of 15 seconds at 95°C and 30 seconds at 60°C. The lengths of the amplicons detected by the CD3, CD8, FOXP3, and CALM2 assays were 72, 97, 71, and 72 bp, respectively, with PCR efficiencies $[E = 1(10^{-\text{slope}})]$ of 106%, 91%, 103%, and 99%, respectively. Samples were considered eligible for further investigation (N = 826, Figure 1) when the cycle threshold (CT) values of the housekeeping gene were $\leq 33.5$ (duplicate mean values). When the difference between the duplicate CT values for a given sample was $>0.50$, the sample was reassessed in triplicates (repeats). Relative expression levels of the target transcripts were calculated as 40-DCT values (DCT = mean CT target gene – mean CT housekeeping gene) to yield positively correlated numbers and to facilitate comparisons.\textsuperscript{34,35,44} CD3, CD8, and FOXP3 results were available for all 826 eligible samples, after the above-mentioned repeats were completed. A commercially available human reference RNA (Stratagene qPCR Human Reference Total RNA, Agilent Technologies) was used as positive control. No-template controls were assessed in parallel to exclude contamination. The qRT-PCR method has recently been validated.\textsuperscript{45}

### 2.7 Statistical analysis

A total of 826 patients with breast cancer were included in this study [Figure 1]. Continuous variables are presented as means (standard deviation) and medians (range), while categorical variables are presented as frequencies (percent, %). The chi-square test was used for group comparisons of categorical data, while Kruskal–Wallis or Mann–Whitney $U$ tests were used for the comparison of continuous variables.
between groups, as appropriate. Spearman’s correlation coefficient was used for estimating the correlations between continuous variables.

Overall survival (OS) was defined as the time (in months) from the date of diagnosis with breast cancer to the date of patient’s death or last contact, while disease-free survival (DFS) was defined as the time (in months) from the date of diagnosis to documented first relapse, death without prior documented relapse or last contact, whichever occurred first.\textsuperscript{46} Surviving patients (for OS and DFS) and patients without relapse (for DFS) were censored at the date of last contact. Women who died without prior relapse were treated as having had relapse at the date of their death. Survival curves were estimated using the Kaplan–Meier method and compared across groups with the log-rank test. The associations between the factors examined and mortality/relapse rate were evaluated with hazard ratios estimated with Cox proportional hazards model. The proportional hazards assumption was tested by evaluating the statistical significance of the time-dependent associations between each variable and relapse/death rates.

The following parameters were studied in relation to DFS/OS: (a) clinicopathological, such as age (≤median, >median), positive lymph nodes (0–3, ≥4 positive lymph nodes), tumor size (≤2, 2–5, >5 cm), chemotherapy treatment with paclitaxel (no, yes), adjuvant hormonal therapy (no, yes), adjuvant radiotherapy (no, yes), breast surgery (breast-conserving surgery, modified radical mastectomy), subtypes (luminal A, luminal B, luminal-HER2, HER2-enriched, triple-negative), Ki67 (continuous), and TILs (10% increments), (b) T-cell mRNA markers considered as 2-level categorical variables (high expression vs low expression) using the 50th percentile (median value) as a cutoff: CD3, CD8, and FOXP3.

We also assessed whether the association of the T-cell mRNA markers was modified by treatment or breast cancer subtype by adding interaction terms in Cox regression analyses between CD3, CD8, and FOXP3 and: chemotherapy treatment with paclitaxel (yes vs no); HER2 status; and ER/PgR status. In multivariate analyses, we estimated the effect (HR) of each of the T-cell mRNA markers adjusted for the effect of the clinicopathological parameters that were statistically significant or marginally significant in the univariate analysis (\(P < 0.10\)).

Finally, the associations between the three T-cell mRNA markers (CD3, CD8, and FOXP3) and the following mRNA markers were examined: RANK (median cutoff: high, low), RANKL (median cutoff: high, low), and OPG (median cutoff: high, low). The bivariate correlations between all mRNA markers, assessed in their original form as continuous variables, were also estimated.

Results of this study were presented according to reporting recommendations for tumor marker prognostic studies.\textsuperscript{27} This study is prospective–retrospective as described in Simon et al.\textsuperscript{47} All analyses were performed in the entire cohort. The
statistical analyses were performed using the SAS software (SAS for Windows, version 9.4, SAS Institute Inc., Cary, NC). Statistical significance was set at 2-sided \( P = 0.05 \).

3 | RESULTS

3.1 | Patient characteristics

Selected patient and tumor characteristics of the 826 patients that were included in the analysis are presented in Table 2. Median age at diagnosis was 52.7 years (range: 22-79), while the majority of patients were postmenopausal (54.2%), ER/PgR-positive (79.0%), and HER2-negative (76.3%).

The distribution of tumor samples based on the normalized expression of mRNA encoding for the three examined markers is presented in Figure 2. The median value of CD3, CD8, and FOXP3 mRNA expressions was 32.9 (range: 23.4-5072), 32.5 (26.8-38.4), and 34.3 (29.5-38.9), respectively. The median age at diagnosis was 52.7 years (range: 22-79), while the majority of patients were postmenopausal (54.2%), ER/PgR-positive (79.0%), and HER2-negative (76.3%).

The distribution of tumor samples based on the normalized expression of mRNA encoding for the three examined markers is presented in Figure 2. The median value of CD3, CD8, and FOXP3 mRNA expressions was 32.9 (range: 23.4-5072), 32.5 (26.8-38.4), and 34.3 (29.5-38.9), respectively. Representative pictures showing different stromal tumor-infiltrating lymphocyte (TIL) densities in the examined breast tumors are shown in Figure 3.

3.2 | Association of mRNA markers with clinicopathological characteristics

The associations of the T-cell mRNA markers and selected clinicopathological parameters are presented in Table 3. ER/PgR-negative, HER2-positive, and grade III-IV tumors had higher CD3 (all Mann–Whitney \( P \)-values \( \leq 0.001 \), CD8 \( (P = 0.007, \ P = 0.038, \text{ and } \ P = 0.002, \) respectively) and FOXP3 (all \( P \)-values \( < 0.001 \)) mRNA expression. In addition, tumors of lower size were found to have higher mRNA expression of CD3 (Kruskal–Wallis test, \( P = 0.001 \)), CD8 \( (P < 0.001) \), and FOXP3 \( (P = 0.018) \), while lower number of positive lymph nodes was associated with higher FOXP3 mRNA expression (Mann–Whitney \( U \) test, \( P = 0.004 \).)

Postmenopausal women were found to have higher mRNA expression of FOXP3 \( (P < 0.001) \) and so did older women (age above the median). Finally, CD3, CD8, and FOXP3 mRNA expressions were significantly associated with breast cancer subtypes (Kruskal–Wallis test, \( P < 0.001 \), \( P = 0.032 \) and \( P < 0.001 \), respectively). The distribution of the study markers by breast cancer subtypes is presented in Figure 4.

3.3 | Association among mRNA markers

CD3 mRNA expression was significantly associated with CD8, FOXP3, RANK, and RANKL mRNA expressions (chi-square test, all \( P \)-values \( < 0.001 \) ) (Table S2). More specifically, high expression of CD3 (\( \geq \) median) was associated with high expression of the rest mRNA markers. Similar were the results for the CD8 and FOXP3 markers, which were also positively associated with one another, as well as with RANK and RANKL mRNA markers. In addition, FOXP3 was positively associated with OPG mRNA expression \( (P = 0.041) \).

Using the continuous measurements of the mRNA markers, the strongest and statistically significant \( (P < 0.001) \) correlations were observed among the T-cell markers: CD3 and CD8 \( (r = 0.70) \); CD3 and FOXP3 \( (r = 0.65) \); and CD8 and FOXP3 \( (r = 0.61) \) (Table S3). Finally, mRNA expression in all three markers was positively correlated with TILs, \( r = 0.52 \) for CD3, \( r = 0.41 \) for CD8 and \( r = 0.47 \) for FOXP3 (all \( P \)-values \( < 0.001 \)) (Table S3). Heatmap of the Spearman correlations between all study markers is shown in Figure 5.

3.4 | Lymph node mRNA expression

CD3, CD8, and FOXP3 mRNA expressions were also measured in 90 available lymph node samples that were paired to the primary tumor samples. A significant correlation of small to medium magnitude was observed between primary tumor and lymph node mRNA expression for the CD8 and FOXP3 markers; Spearman’s \( r = 0.27 \) \( (P = 0.010) \) and \( r = 0.29 \) \( (P = 0.005) \), respectively. No significant correlation in the CD3 expression between the two tissues was observed \( (r = 0.16, \ P = 0.12) \) [results are not presented].

3.5 | Markers effect on outcome

Survival status of all patients was updated in June 2014. Within a median follow-up time of 133 months (range 0.1-218.8), 255 deaths (30.9%) and 314 relapses occurred (38%). Of note, 279 of the 314 relapsed patients (88.9%) had bone metastases. Median OS was reached at 201.1 months, while median DFS was 201.3 months.

Results from univariate Cox regression analyses for each of the three T-cell markers with respect to DFS and OS are presented in Table S4. Low, as compared to high, CD3 and CD8 mRNA expression was associated with increased relapse rate. More specifically, patients with low CD3 and CD8 mRNA expression had, respectively, 36% and 32% increased risk of relapse compared to patients with high mRNA expression of those markers. Kaplan–Meier curves for DFS based on CD3, CD8, and FOXP3 mRNA expressions are presented in Figure 6. FOXP3 mRNA expression was not significantly associated with DFS. Finally, none of the markers had a significant effect on mortality rate.

Results from univariate Cox regression analyses in the entire cohort for each of the clinicopathological parameters are presented in Table S5. Age, breast surgery, menopausal status, tumor size, positive lymph nodes, ER/PgR status, Ki67, TILs, subtypes, adjuvant hormonal therapy, and adjuvant radiotherapy were statistically significant or marginally significant in the univariate analysis for DFS and OS. Results from multivariate analyses including the aforementioned clinicopathological parameters (excluding menopausal status
and ER/PgR status/hormonal therapy/Ki67 due to their high correlation with age and subtypes, respectively) and each of the significant T-cell mRNA markers with respect to DFS are presented in Table 4. The HRs associated with CD3 and CD8 mRNA expression adjusted for the rest of the clinicopathological variables were of similar magnitude as the unadjusted hazard ratios. More specifically, low CD3, as well as low CD8 mRNA expression, remained unfavorable prognostic factors for DFS (adjusted HR = 1.30, 95% CI 0.99-1.69, \(P = 0.059\) and HR = 1.30, 95% CI 1.00-1.68, \(P = 0.048\), respectively).

None of the three mRNA markers (CD3-CD8-FOXP3) was found to be differentially associated with DFS or OS according to paclitaxel therapy (\(P\)-interaction: 0.39, 0.43 and 0.65 for DFS; 0.77, 0.66, and 0.96 for OS, respectively), suggesting lack of predictive value of the markers for paclitaxel treatment. Also, no significant interaction was observed between any of the three T-cell markers and

---

**Table 2** (Continued)

| Parameters | N (%)       |
|------------|-------------|
| ER/PgR status |           |
| Informative N (%) | 770 (93.2%) |
| Positive | 608 (79.0%) |
| Negative | 162 (21.0%) |
| HER2 status |           |
| Informative N (%) | 778 (94.2%) |
| Positive | 184 (23.7%) |
| Negative | 594 (76.3%) |
| Ki67 |             |
| Informative N (%) | 767 (92.9%) |
| Mean (SD) | 31.4 (24.3) |
| Median (min-max) | 25 (0-98) |
| TILs |             |
| Informative N (%) | 786 (95.2%) |
| Mean (SD) | 12.6 (14.8) |
| Median (min-max) | 8 (0-90) |
| Subtypesa |           |
| Informative N (%) | 757 (91.6%) |
| Luminal A | 229 (30.3%) |
| Luminal B | 263 (34.7%) |
| Luminal-HER2 | 103 (13.6%) |
| HER2-enriched | 78 (10.3%) |
| Triple-negative | 84 (11.1%) |

*Breast cancer subtypes defined by immunohistochemistry: luminal A (ER-positive and/or PgR-positive, HER2-negative, Ki67low); luminal B (ER-positive and/or PgR-positive, HER2-negative, Ki67high); luminal-HER2 (ER-positive and/or PgR-positive, HER2-positive); HER2-enriched (ER-negative, PgR-negative, HER2-positive); and triple-negative (ER-negative, PgR-negative, and HER2-negative).*
ER/PgR status ($P$-interaction: 0.11, 0.87, and 0.39 for DFS; 0.43, 0.46, and 0.59 for OS, respectively). Of note, a significant interaction was observed between HER2 status and CD3 with respect to DFS ($P$-interaction = 0.032), while a marginally significant interaction was observed between FOXP3 and HER2 status with respect to OS ($P$-interaction $P = 0.065$) (Table S4). In the HER2-positive and HER2-negative subgroups of patients, the unadjusted HR (95% CI) of DFS associated with low CD3 expression was 2.08 (1.31-3.31), $P = 0.002$ and 1.20 (0.92-1.56), $P = 0.19$, respectively. Similarly, the unadjusted HR (95% CI) of OS associated with low FOXP3 in the HER2-positive and HER2-negative subgroups of patients was as follows: 1.76 (1.07-2.88), $P = 0.026$ and 0.98 (0.72-1.33), $P = 0.89$, respectively. In multivariate models, only the interaction between CD3 expression and HER2 status was statistically significant (adjusted $P$-interaction = 0.037); however, the associations between any of the three T-cell markers and DFS or OS among the HER2-positive or HER2-negative subgroups were of no statistical significance (Table S6). Similarly, in the triple-negative subgroup, none of the three examined markers showed any prognostic significance with respect to DFS (Table S7).

4 | DISCUSSION

Primary goal of our study was to evaluate the prognostic value of CD3, CD8, and FOXP3 mRNA expressions, as markers for T-cell infiltration, in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy in the context of two prospective phase III randomized trials. Furthermore, following results of a recent work of our group, we investigated the association of RANK, RANKL, and OPG mRNA expressions with the above TILs subpopulations. Our results showed that aggressive tumors (high Ki67 protein expression) present with high CD3 mRNA expression. Likewise, high CD3, CD8, or FOXP3 mRNA expression was more frequently detected in tumors of higher histological grade and negative ER/PgR status. In the univariate analyses, high CD3 and CD8 mRNA expression was found to be of favorable prognostic value for DFS. In the multivariate analyses, the association of high CD8 mRNA expression with increased DFS was retained, whereas that of high CD3 mRNA expression was of marginal statistical significance. None of the markers was found to be of predictive value for paclitaxel treatment, despite the fact that all three markers were more highly expressed in paclitaxel-treated patients; the lack of predictive value was probably due to the small number of patients that were not treated with paclitaxel (17% of the total population). Moreover, a significant interaction was observed between HER2 status and CD3 mRNA expression with respect to DFS. In the HER2-positive subgroup, the hazard ratio associated with high CD3 mRNA expression was of greater magnitude compared to the hazard ratio for the entire cohort.

In the present study, CD3 and CD8 mRNA derives solely from TILs, as no staining of CD3 or CD8 has ever been reported in breast cancer cells, whether such staining was evaluated by classic IHC48 or the AQUA method.49 As for FOXP3, a very small percentage of breast cancer cells might show weak nuclear staining, which is detectable in only 1% of breast cancer cases.50 Therefore, most if not all of the FOXP3 mRNA expression detected in our study comes from TILs, as well and not tumor cells.

Our results demonstrate that the extent of effector lymphocyte infiltration affects survival in BC, even when we analyzed all BC variants together. Mahmoud et al51 found that tumor infiltration by high numbers of CD8-positive T lymphocytes is an independent prognostic factor for improved survival in BC patients. Despite that, the clinical significance of TILs is more pronounced in more aggressive subtypes and in the absence of hormone receptors. Our findings are in accordance with those from other large clinical trials, which showed a strong association of increased lymphocyte infiltration and improved outcomes in more aggressive BC subtypes, such as TN and ER/PgR-negative/HER2-positive patients. A total of 2009 node-positive breast cancer samples from the BIG 02-98 adjuvant phase...
III trial were analyzed for TILs and results showed that in HER2-positive patients, increased lymphocyte infiltration was significantly associated with benefit from anthracycline-only chemotherapy. These findings were confirmed in an analysis using samples from the FinHER adjuvant phase III trial, where in TN patients and HER2-positive patients receiving trastuzumab, each 10% increase in lymphocytic infiltration was significantly associated with decreased distant recurrence. Both TN and HER2-positive patients exhibit relatively higher numbers of TILs compared to their hormone positive counterparts, with the major effect in survival benefit attributed to CD8-positive lymphocytes. Liu et al performed IHC for CD8 staining in 3992 breast cancer samples and demonstrated that in TN patients, intratumoral or stromal infiltration by CD8-positive lymphocytes is an independent favorable prognostic factor for BC-specific survival (BCSS). Ali et al used 12,439 samples from breast cancer patients and quantified CD8-positive lymphocyte infiltration by IHC. They found that the presence of intratumoral or stromal CD8-positive lymphocytes was associated with reduced BC-specific mortality in ER-negative tumors (TN and HER2-positive). However, in ER-positive tumors, that was not the case. Nevertheless, there was an association of CD8-positive lymphocyte infiltration with increased BC-specific survival in ER-positive/HER2-positive tumors. A systematic meta-analysis was recently performed by Mao et al including 22,964 BC patients from 22 studies and demonstrated, as in our study, that infiltrating CD8-positive lymphocytes were correlated with better DFS and BCSS, but not OS, in the overall population. Moreover, there was an association with improved BCSS in ER-negative, HER2-positive, and TN subtypes, but not in the ER-positive one.

The prognostic value of FOXP3-positive Tregs in BC is not so clear and results of several studies are controversial. Tregs may be recruited by the tumors and can suppress the antitumor activity of effector T cells in the tumor site. In our study, we showed that FOXP3-positive Treg infiltration is not associated with DFS or OS in the overall BC population. Bates et al demonstrated that in BC samples, high rate of Treg infiltration was more frequent in patients with ER-negative, high-grade tumors, and positive lymph nodes and that it was associated with poor outcomes, even in ER-positive tumors. Our finding showing that patients with ER/PgR-negative, HER2-positive, and grade III-IV tumors had higher FOXP3 mRNA expression are in agreement with Bates et al; however, in our study, higher FOXP3 mRNA expression was not associated with outcome. On the contrary, Liu et al found that high numbers of FOXP3-positive cells in HER2-positive tumors may predict chemosensitivity, whereas Lee et al demonstrated that patients with highly infiltrated TN tumors by Tregs have improved survival. Mao et al showed in a large meta-analysis that high Treg infiltration was associated with poor OS and BCSS only in ER-positive patients and not in ER-negative patients. Finally, in our study, postmenopausal women were found to have higher FOXP3 mRNA expression and so did older women.
| TABLE 3 | Associations between continuous mRNA expression values and selected clinicopathological characteristics |
|----------------|-------------------------------------------------|----------------|----------------|
|               | **CD3**                                          | **CD8**        | **FOXP3**      |
|               | N      | Median | Range  | P-value | N      | Median | Range  | P-value | N      | Median | Range  | P-value |
| Age (median cutoff) |       |        |        |         |       |        |        |         |       |        |        |         |
| ≤52.7          | 415    | 32.8   | (23.4-37.9) | 0.16  | 415    | 32.5   | (26.8-38.4) | 0.35  | 415    | 34.2   | (29.5-38.5) | <0.001* |
| >52.7          | 411    | 33.0   | (25.4-38.6) | 0.66  | 411    | 32.5   | (27.4-38.0) | 0.19  | 411    | 34.6   | (29.7-38.9) | <0.001* |
| Menopausal status |       |        |        |         |       |        |        |         |       |        |        |         |
| Postmenopausal | 448    | 33.0   | (25.4-38.6) | 0.66  | 448    | 32.6   | (27.4-38.0) | 0.19  | 448    | 34.6   | (29.7-38.9) | <0.001* |
| Premenopausal  | 378    | 32.9   | (23.4-37.9) | 0.06  | 378    | 32.4   | (26.8-38.4) | 0.19  | 378    | 34.1   | (29.5-38.5) |         |
| Breast surgery |       |        |        |         |       |        |        |         |       |        |        |         |
| Breast-conserving | 242    | 33.4   | (23.4-38.6) | 0.014* | 242    | 32.6   | (27.5-37.4) | 0.18  | 242    | 34.6   | (30.1-38.9) | 0.013* |
| Modified radical mastectomy | 583    | 32.8   | (25.3-38.5) | 0.001* | 583    | 32.5   | (26.8-38.4) | 0.18  | 583    | 34.2   | (29.5-38.5) |         |
| Tumor size (in cm) |       |        |        |         |       |        |        |         |       |        |        |         |
| ≤2             | 252    | 33.2   | (27.2-38.6) | 0.001* | 252    | 32.8   | (26.8-37.6) | <0.001* | 252    | 34.5   | (30.0-38.9) | 0.018* |
| >2             | 472    | 32.8   | (23.4-38.5) | 0.001* | 472    | 32.4   | (27.2-38.4) | 0.001* | 472    | 34.4   | (29.5-38.4) |         |
| 2-5            | 102    | 32.7   | (26.6-37.9) | 0.001* | 102    | 32.0   | (28.2-36.0) | 0.001* | 102    | 33.8   | (30.1-37.8) |         |
| Positive lymph nodes |       |        |        |         |       |        |        |         |       |        |        |         |
| 0-3            | 335    | 33.1   | (25.3-38.6) | 0.10  | 335    | 32.6   | (26.8-38.0) | 0.64  | 335    | 34.5   | (29.5-38.9) | 0.004* |
| ≥4             | 491    | 32.8   | (23.4-37.9) | 0.001* | 491    | 32.4   | (27.2-38.4) | 0.001* | 491    | 34.2   | (30.0-38.5) |         |
| Paclitaxel treatment |     |        |        |         |       |        |        |         |       |        |        |         |
| Non paclitaxel-treated | 141    | 32.1   | (23.4-36.0) | <0.001* | 141    | 31.8   | (26.8-36.3) | <0.001* | 141    | 33.6   | (29.5-36.9) | <0.001* |
| Paclitaxel-treated  | 685    | 33.1   | (25.3-38.6) | 0.001* | 685    | 32.6   | (27.7-38.4) | 0.001* | 685    | 34.5   | (29.7-38.9) |         |
| Adjuvant hormonal therapy |     |        |        |         |       |        |        |         |       |        |        |         |
| No             | 150    | 33.9   | (28.5-37.9) | <0.001* | 150    | 33.2   | (28.9-36.7) | <0.001* | 150    | 35     | (30.1-38.5) | <0.001* |
| Yes            | 660    | 32.8   | (23.4-38.6) | 0.001* | 660    | 32.3   | (26.8-38.4) | 0.001* | 660    | 34.2   | (29.5-38.9) |         |
| Adjuvant radiotherapy |     |        |        |         |       |        |        |         |       |        |        |         |
| No             | 181    | 33.1   | (28.0-38.5) | 0.52  | 181    | 32.6   | (26.8-38.0) | 0.85  | 181    | 34.3   | (29.5-38.4) | 0.26   |
| Yes            | 624    | 32.9   | (23.4-38.6) | 0.52  | 624    | 32.5   | (27.2-38.4) | 0.85  | 624    | 34.3   | (29.9-38.9) |         |
| Histological grade |     |        |        |         |       |        |        |         |       |        |        |         |
| I-II           | 409    | 32.7   | (23.4-38.6) | 0.001* | 409    | 32.2   | (27.2-37.4) | 0.002* | 409    | 34.0   | (29.5-38.9) | <0.001* |
| III-IV         | 416    | 33.2   | (25.3-38.5) | 0.001* | 416    | 32.7   | (26.8-38.4) | 0.001* | 416    | 34.7   | (29.9-38.5) |         |

(Continues)
### Table 3 (Continued)

| Subtype            | CD3 N | CD3 Median | CD3 Range | CD3 P-value | CD8 N | CD8 Median | CD8 Range | CD8 P-value | FOXP3 N | FOXP3 Median | FOXP3 Range | FOXP3 P-value |
|--------------------|-------|------------|-----------|-------------|-------|------------|-----------|-------------|-------|-------------|------------|---------------|
| **ER/PgR status**  |       |            |           |             |       |            |           |             |       |            |           |               |
| Negative           | 162   | 33.5       | (23.4-37.7)| <0.001*     | 162   | 32.9       | (27.5-37.6)| 0.007*      | 162   | 34.8        | (30.9-38.5)| <0.001*       |
| Positive           | 608   | 32.8       | (25.3-38.6)|             | 608   | 32.3       | (26.8-38.4)|             | 608   | 34.2        | (29.5-38.9)|               |
| **HER2 status**    |       |            |           |             |       |            |           |             |       |            |           |               |
| Negative           | 594   | 32.7       | (25.4-38.6)| <0.001*     | 594   | 32.4       | (26.8-37.6)| 0.038*      | 594   | 34.2        | (29.5-38.9)| <0.001*       |
| Positive           | 184   | 33.6       | (23.4-38.5)|             | 184   | 32.7       | (27.5-38.4)|             | 184   | 34.9        | (30.7-38.5)|               |
| **Ki67**           |       |            |           |             |       |            |           |             |       |            |           |               |
| Low (<20%)         | 295   | 32.6       | (26.6-38.6)| 0.038*      | 295   | 32.5       | (26.8-37.4)| 0.59        | 295   | 34.2        | (29.7-38.7)| 0.15          |
| High (≥20%)        | 472   | 33.1       | (23.4-38.5)|             | 472   | 32.5       | (27.4-38.4)|             | 472   | 34.4        | (29.5-38.5)|               |
| **Subtypes**       |       |            |           |             |       |            |           |             |       |            |           |               |
| Luminal A          | 229   | 32.6       | (26.6-38.6)| <0.001*     | 229   | 32.4       | (26.8-37.4)| 0.032*      | 229   | 34.1        | (29.7-38.9)| <0.001*       |
| Luminal B          | 263   | 32.7       | (25.4-37.9)|             | 263   | 32.2       | (27.4-36.9)|             | 263   | 34.2        | (29.5-38.1)|               |
| Luminal-HER2       | 103   | 33.5       | (25.3-38.5)|             | 103   | 32.5       | (28.3-38.4)|             | 103   | 34.8        | (30.7-38.4)|               |
| HER2-enriched      | 78    | 33.7       | (23.4-37.7)|             | 78    | 33.1       | (27.5-36.8)|             | 78    | 35.0        | (30.9-38.5)|               |
| Triple-negative    | 84    | 33.2       | (28.5-37.0)|             | 84    | 32.8       | (27.7-37.6)|             | 84    | 34.6        | (31.7-38.5)|               |

Significant P-values are shown in bold.

* Mann–Whitney U test.

** For breast cancer subtype classification please see footnote to Table 2.

^ Kruskal–Wallis test.
The latter is in agreement with Gregg et al. showing that circulating Tregs are increasing with age in healthy subjects, while it appears that the observed higher mRNA expression of FOXP3 in postmenopausal women with breast cancer is reflecting the general increase in Tregs with age.

The RANK/OPG/RANKL pathway in BC is involved in many intracellular processes, and its role as prognostic factor for BCSS or the formation of bone metastasis is unclear. We have recently shown that low RANKL mRNA expression in tumor tissue is associated with reduced DFS and bone metastases development, but other studies have demonstrated conflicting results. In the current study, we found that there is a strong association of high RANK and RANKL mRNA expression with CD3-positive, CD8-positive, and FOXP3-positive lymphocytes, while high OPG mRNA expression was associated only with FOXP3-positive infiltrating lymphocytes. This novel finding could possibly mean...
that the inactivation of the RANK/RANKL pathway, resulting from increased mRNA expression of the decoy receptor OPG, might induce Treg recruitment in the tumor site or vice versa. To elucidate that, a series of preclinical and clinical studies are needed in order to make a therapeutic intervention, for example, administration of RANKL inhibitor, to abrogate Treg-mediated immunosuppression at the tumor site.

In conclusion, our study is the first, to our knowledge, that used CD3, CD8, and FOXP3 mRNA expression as surrogate markers of T-cell infiltration and examined the prognostic value of such markers in BC. Limitations of our study includes the relative disadvantages of using mRNA from FFPE samples due to RNA degradation and fragmentation during the fixation process and the missing information of the spatial distribution of immune cells within the tumor in comparison with the IHC method; with the latter limitation in mind, we are in the process of evaluating CD3, CD8, and FOXP3 protein expression in the same patient cohort, in order to verify

### Table 4

Hazard ratios and 95% CIs estimated from multivariate Cox regression with respect to DFS for each of the study markers that were significant in the univariate analyses (N = 705)

| Parameters          | Categories                          | N patients | N events | HR   | 95% CI  | Wald’s P |
|---------------------|-------------------------------------|------------|----------|------|--------|----------|
| Model 1             |                                     |            |          |      |        |          |
| CD3 (median cut-off)| Low vs High                         | 351 vs 354 | 153 vs 112 | 1.30 | 0.99 | 1.69 | 0.059 |
| Age                 | >52.7 vs ≤52.7                      | 352 vs 353 | 146 vs 119 | 1.23 | 0.96 | 1.58 | 0.098 |
| Breast surgery      | MRM vs Breast-conserving            | 494 vs 211 | 205 vs 60  | 1.40 | 1.03 | 1.90 | 0.033 |
| Tumor size          | 2-5 vs ≤2                           | 406 vs 212 | 157 vs 65  | 1.19 | 0.88 | 1.59 | 0.26  |
| Positive lymph nodes| ≥4 vs 0-3                           | 426 vs 279 | 201 vs 64  | 2.09 | 1.50 | 2.93 | <0.001|
| Subtypes*a          | Luminal B vs Luminal A              | 242 vs 210 | 93 vs 66   | 1.27 | 0.92 | 1.74 | 0.15  |
|                     | Luminal-HER2 vs Luminal A           | 95 vs 210  | 39 vs 66   | 1.69 | 1.12 | 2.55 | 0.013 |
|                     | HER2-enriched vs Luminal A          | 76 vs 210  | 28 vs 66   | 1.44 | 0.91 | 2.27 | 0.12  |
|                     | Triple-negative vs Luminal A        | 82 vs 210  | 39 vs 66   | 2.15 | 1.43 | 3.23 | <0.001|
| Adjuvant radiotherapy| Yes vs No                          | 550 vs 155 | 220 vs 45  | 1.02 | 0.69 | 1.50 | 0.92  |
| TILs (10% increments)|                                  |            |          | 0.89 | 0.81 | 0.99 | 0.031 |
| Model 2             |                                     |            |          |      |        |          |
| CD3 (median cutoff) | Low vs High                         | 351 vs 354 | 153 vs 112 | 1.30 | 1.00 | 1.68 | 0.048 |
| Age                 | >52.7 vs ≤52.7                      | 352 vs 353 | 146 vs 119 | 1.22 | 0.95 | 1.56 | 0.12  |
| Breast surgery      | MRM vs Breast-conserving            | 494 vs 211 | 205 vs 60  | 1.41 | 1.03 | 1.91 | 0.030 |
| Tumor size          | 2-5 vs ≤2                           | 406 vs 212 | 157 vs 65  | 1.17 | 0.88 | 1.57 | 0.29  |
| Positive lymph nodes| ≥4 vs 0-3                           | 426 vs 279 | 201 vs 64  | 2.12 | 1.52 | 2.97 | <0.001|
| Subtypes*a          | Luminal B vs Luminal A              | 242 vs 210 | 93 vs 66   | 1.25 | 0.91 | 1.71 | 0.18  |
|                     | Luminal-HER2 vs Luminal A           | 95 vs 210  | 39 vs 66   | 1.63 | 1.08 | 2.46 | 0.020 |
|                     | HER2-enriched vs Luminal A          | 76 vs 210  | 28 vs 66   | 1.40 | 0.89 | 2.20 | 0.15  |
|                     | Triple-negative vs Luminal A        | 82 vs 210  | 39 vs 66   | 2.13 | 1.42 | 3.20 | <0.001|
| Adjuvant radiotherapy| Yes vs No                          | 550 vs 155 | 220 vs 45  | 1.02 | 0.69 | 1.50 | 0.93  |
| TILs (10% increments)|                                  |            |          | 0.89 | 0.80 | 0.98 | 0.018 |

HR, hazard ratio; CI, confidence interval; MRM, modified radical mastectomy.

Significant P-values are shown in bold.

*aFor breast cancer subtype classification please see footnote to Table 2.
whether the qRT-PCR findings correlate to the IHC results. Nevertheless, our study clearly showed that high CD8 mRNA expression is associated with improved outcome in BC and such prognostic value is more profound in the HER2-positive subtype. This is in agreement with other studies that used IHC for TILs evaluation. Moreover, due to the fact that we included patients from randomized trials before trastuzumab was approved as adjuvant treatment, our findings are unbiased from its use in the adjuvant setting. Further investigations of the role of TIL subtypes and their interactions with other immune cells, such as TAMs, as well as other factors and pathways, such as the RANK/OPG/RANKL pathway, could guide immunotherapeutic decisions in the future.

ORCID

Marinos Tsiatas http://orcid.org/0000-0002-5881-992X

REFERENCES

1. Dieu-Nosjean MC, Antoine M, Daniel C, et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008;26(27):4410-4417.

2. Pages F, Kirilovsky A, Mlecnik B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 2009;27(35):5944-5951.

3. Hwang WT, Adams SP, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124(2):192-198.

4. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunology. Annu Rev Immunol. 2004;22:329-360.

5. Denkert C, Loibl S, Noske A, et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2010;28(1):105-113.

6. Kotoula V, Chatzopoulos K, Lakis S, et al. Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. Oncotarget. 2016;7(4):5074-5087.

7. Adams S, Gray RJ, Demaria S, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959-2966.

8. Loi S, Michiels S, Salgado R, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544-1550.

9. Dieci MV, Mathieu MC, Guarneri V, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials. Ann Oncol. 2015;26(8):1698-1704.

10. Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res. 2012;14(2):R48.

11. Kotoula V, Karavasilis V, Zagouri F, et al. Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. Breast Cancer Res Treat. 2016;158(2):307-321.

12. Stanton SE, Adams S, Disis ML. Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol. 2016;2(10):1354-1360.

13. Mostafa AA, Codner D, Hisawawa K, et al. Activation of E-RAdha signaling differentially modulates IFN-gamma induced HLA-class II expression in breast cancer cells. PLoS ONE. 2014;9(1):e87377.

14. Chung YR, Kim HJ, Jang MH, Park SY. Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status. Breast Cancer Res Treat. 2017;161(3):409-420.

15. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol. 2006;24(34):5373-5380.

16. Liu F, Lang R, Zhao J, et al. CD8(+)-cytotoxic T cell and FOXP3(+)- regulatory T cell infiltration in relation to breast cancer survival and molecular subtypes. Breast Cancer Res Treat. 2011;130(2):645-655.

17. Ladoire S, Mignot G, Dalban C, et al. FOXP3 expression in cancer cells and antracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. Ann Oncol. 2012;23(10):2552-2561.

18. Mundt GR. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer. 2002;2(8):584-593.

19. Timotheou E, Kalogeras KT, Koliou GA, et al. Evaluation of the prognostic value of RANK, OPG, and RANKL mRNA expression in early breast cancer patients treated with antracycline-based adjuvant chemotherapy. Transl Oncol. 2017;10(4):589-598.

20. Dougall WC. RANKL signaling in bone physiology and cancer. Curr Opin Support Palliat Care. 2007;1(4):317-322.

21. Fountzilas G, Skarlos D, Dafni U, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2005;16(11):1762-1771.

22. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thirlimann B, Senn HJ. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol. 2007;18(7):1133-1144.

23. Fountzilas G, Dafni U, Gogas H, et al. Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol. 2007;19(5):853-860.

24. Gogas H, Dafni U, Karina M, et al. Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treat. 2012;132(2):609-619.

25. Razis E, Bobos M, Kotoula V, et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat. 2011;128(2):447-456.
26. Fountzilas G, Dafni U, Bobos M, et al. Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. *PLoS ONE*. 2012;7(6):e37946.

27. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumour MARKer prognostic studies (REMARK). *Br J Cancer*. 2005;93(4):387-391.

28. Kononen J, Bubendorff L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. *Nat Med*. 1998;4(7):844-847.

29. Skacel M, Skilton B, Pettay JD, Tubbs RR. Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimens: a review of the method with validation data. *Appl Immunohistochem Mol Morphol*. 2002;10(1):1-6.

30. Salgado R, Denkert C, Demaria S, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. *Ann Oncol*. 2015;26(2):259-271.

31. Fountzilas G, Kourea HP, Bobos M, et al. Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. *Anticancer Res*. 2011;31(9):3007-3018.

32. Psyrri A, Kalogeras KT, Kronenwett R, et al. Prognostic significance of UBE2C mRNA expression in high-risk early breast cancer. A Hellenic Cooperative Oncology Group (HeCOG) Study. *Ann Oncol*. 2011;23(6):1422-1427.

33. Fountzilas G, Dafni U, Bobos M, et al. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. *BMC Cancer*. 2013;13(1):163.

34. Stavridi F, Kalogeras KT, Pliarchopoulou K, et al. Comparison of the ability of different clinical treatment scores to estimate prognosis in high-risk early breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) Study. *PLoS ONE*. 2016;11(10):e0164013.

35. Psyrri A, Kalogeras KT, Wirtz RM, et al. Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. *J Transl Med*. 2017;15(1):30.

36. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. *J Clin Oncol*. 2007;25(1):118-145.

37. Hammond ME, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. *J Clin Oncol*. 2010;28(16):2784-2795.

38. Romero Q, Bendahl PO, Ferno M, Grabau D, Borgquist S. A novel model for Ki67 assessment in breast cancer. *Diagn Pathol*. 2014;9:118.

39. Bartlett JM, Munro AF, Dunn JA, et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). *Lancet Oncol*. 2010;11(3):266-274.

40. Press MF, Sauter G, Buyse M, et al. Alteration of Topoisomerase II–Alpha Gene in Human Breast Cancer: association with Responsiveness to Anthracycline-Based Chemotherapy. *J Clin Oncol*. 2011;29(7):859-867.

41. Vanden Bempt I, Van Loo P, Drijkoningen M, et al. Polysomy 17 in breast cancer: clinicopathologic significance and impact on HER-2 testing. *J Clin Oncol*. 2008;26(30):4869-4874.

42. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. *J Clin Oncol*. 2009;27(8):1323-1333.

43. Pentheroudakis G, Kotoula V, Eleftheraki AG, et al. Prognostic significance of ESR1 gene amplification, mRNA/protein expression and functional profiles in high-risk early breast cancer: a translational study of the Hellenic Cooperative Oncology Group (HeCOG). *PLoS ONE*. 2013;8(7):e70634.

44. Pentheroudakis G, Raptou G, Kotoula V, et al. Immune response gene expression in colorectal cancer carries distinct prognostic implications according to tissue, stage and site: a prospective retrospective translational study in the context of a Hellenic Cooperative Oncology Group randomised trial. *PLoS ONE*. 2015;10(5):e0124612.

45. Laible M, Schlombs K, Kaiser K, et al. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens. *BMC Cancer*. 2016;16:398.

46. Hudis CA, Barlow WE, Costantino JP, et al. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. *J Clin Oncol*. 2007;25(15):2127-2132.

47. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. *J Natl Cancer Inst*. 2009;101(21):1446-1452.

48. Ziai J, Gilbert HN, Foreman O, et al. CD8+ T cell infiltration in breast and colon cancer: a histologic and statistical analysis. *PLoS ONE*. 2018;13(1):e0190158.

49. Brown JR, Wimberly H, Lannin DR, Nixon C, Rimm DL, Bossuyt V. Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer. *Cancer Res*. 2014;20(23):5995-6005.

50. Drosner RA, Obermann EC, Wolf AM, Wallner S, Wolf D, Tzankov A. Negligible nuclear FOXP3 expression in breast cancer. *Clin Exp Immunol*. 2013;174(1):1-6.

51. Mahmoud SM, Paish EC, Powe DG, et al. Tumor-infiltrating lymphocytes predict clinical outcome in breast cancer. *J Clin Oncol*. 2011;29(15):1949-1955.

52. Looi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. *Cancer Res*. 2014;13(4):358-364.

53. Mohamed SM, Paish EC, Powe DG, et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. *Cancer Res*. 2011;71(15):5999-6005.

54. Loi S, Sirtaine N, Piette F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer. *Cancer Res*. 2013;71(7):3624-3629.

55. Ali HR, Provenzano E, Dawson SJ, et al. Association between tumor-infiltrating lymphocytes and breast cancer survival in 12,439 patients. *Ann Oncol*. 2014;25(8):1536-1543.

56. Mao Y, Qi Q, Chen X, Huang O, Wu J, Shen K. The prognostic value of tumor-infiltrating lymphocytes in breast cancer. *Cancer Med*. 2015;4(1):212-223.
cancer: a systematic review and meta-analysis. PLoS ONE. 2016;11(4):e0152500.

55. Lee S, Cho EY, Park YH, Ahn JS, Im YH. Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncol. 2013;52(1):73-81.

56. Gregg R, Smith CM, Clark FJ, et al. The number of human peripheral blood CD4+ CD25 high regulatory T cells increases with age. Clin Exp Immunol. 2005;140(3):540-546.

57. Santini D, Schiavon G, Vincenzi B, et al. Receptor activator of NF-κB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS ONE. 2011;6(4):e19234.

58. Owen S, Ye L, Sanders AJ, Mason MD, Jiang WG. Expression profile of receptor activator of nuclear-kappaB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Res. 2013;33(1):199-206.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Tsiatas M, Kalogeras KT, Manousou K, et al. Evaluation of the prognostic value of CD3, CD8, and FOXP3 mRNA expression in early-stage breast cancer patients treated with anthracycline-based adjuvant chemotherapy. Cancer Med. 2018;7:5066–5082. https://doi.org/10.1002/cam4.1730